– Companies to Leverage Lead Product Candidate from IGM’s Proprietary IgM Antibody Platform with ZYNLONTA® for Novel Combination Therapy in Relapsed/Refractory B Cell NHL –– Phase 1 Trial Expected to be Initiated in 1Q23 –MOUNTAIN VIEW, Calif. & LAUSANNE, Switzerland (BUSINESS WIRE) IGM Biosciences, Inc. (Nasdaq:.
- Companies to Leverage Lead Product Candidate from IGM's Proprietary IgM Antibody Platform with ZYNLONTA for Novel Combination Therapy in Relapsed/Refractory B Cell NHL - - Phase 1 Trial Expected